Conversely, GCGR agonism is increasingly seen as a viable component of multi-incretin treatment for obesity and diabetes as, when combined with GLP-1R agonism, beneficial effects of glucagon (e.g. amelioration of hepatic steatosis and increased energy expenditure) may be realised without unwanted hyperglycaemia [63]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.